Skip to content

effect of shigru taila nasya and pippalyadigana vati in vataja pratishyaya (allergic rhinitis)

Evaluation of shigru taila nasya and pippalyadigana vati in the management of vataja pratishyaya (allergic rhinitis)-A comparative clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020155
Enrollment
40
Registered
2019-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Group A: Group A 20 patients,3 sitting of Marsha nasya (nasal route) with shigru taila 8drops in each nostril for 7 days each will given with a gap of 7 days in between each sitting and

Sponsors

Rishikul campus
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients fullfill the diagnostic criteria based on sign and symptoms of vataja pratishyaya and allergic rhinitis Minimum 3 recurrent attack of sign and symptoms of vataja pratishyaya and allergic rhinitis

Exclusion criteria

Exclusion criteria: Patients suffering from chronic or acute sinusitis, rhinitis other than allergic rhinitis, other nasal pathology like DNS., polyp Patients suffering from any chronic systemic disease like Dm, HTN, tuberculosis, lower respiratory tract disease Patients who have taken any antihistaminic, mast cell stabilizer, nasal corticosteroid or any other nasal anatomic variants in nose since two weeks

Design outcomes

Primary

MeasureTime frame
Cured 90% relief in sign and symptoms Marked improvement 76-90% Moderate improvement 51-75% Mild improvement 26-59% No improvement less than 25%Timepoint: 35 days

Secondary

MeasureTime frame
aggravation of symptomsTimepoint: 1 month

Countries

India

Contacts

Public ContactDr Renu Rao

Rishika campus haridwar UAU

docrenuprasad@gmail.com8077151820

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026